CELC Launches REVTORPYK in the U.S. for HR+/HER2- Advanced Breast Cancer Without PIK3CA Mutation
Market Chameleon (Wed, 30-Sep 9:41 AM)
Celcuity says REVTORPYK is now commercially available in the U.S., expanding access after July FDA approval
Market Chameleon (Wed, 30-Sep 9:19 AM)
